Keyword: Cialis

In CEO David Ricks' first year running the show, Eli Lilly posted nearly 8% revenue growth to $22.87 billion, beating the high end of its own guidance of $22.7 billion set in the third-quarter report.

Erectile dysfunction blockbuster Cialis was on FiercePharma’s patent expiration list last year, but Eli Lilly managed to score a few more months of exclusivity in a July settlement with multiple generic drugmakers.

Each year, dozens of branded pharmaceutical products lose their legal lock on the market, paving the way for cheap generic competitors and the sales hit they bring—and for patients, pricing relief in costly drug categories. This year is no different, featuring some serious sales heft and household names at the top of the list.